2076975 2077203
최종편집 2024-03-28 20:29 (목)
Daewon Pharmaceutical Codaewon SㆍBoryung Pharmaceutical Akarb, the stars in the first half
상태바
Daewon Pharmaceutical Codaewon SㆍBoryung Pharmaceutical Akarb, the stars in the first half
  • Hyeokgi Lee, Newsmp
  • 승인 2021.07.26 18:34
  • 댓글 0
이 기사를 공유합니다

1st and 2nd among new drugs… 11 products over 1 billion won 

Daewon Pharmaceutical’s Codaewon S recorded the highest number of prescriptions in the first half among new drugs in the outpatient prescription market.

A total of 11 new drugs listed in the outpatient prescription market since the second half of last year have achieved more than 1 billion won in the first half, according to the UBIST.

Codaewon S recorded prescription sales of 3.7 billion won during the first half of the year and was the only drug to exceed 3 billion won.

Following Codaewon S, Akarb (Boryung Pharmaceutical) made 2.9 billion won in prescription sales and ranked 2nd by nearly double the third place. 

Selebeta     (Chong Kun Dang Pharmaceutical) and Choline Max (Cosmax Pharma) both surpassed 1.5 billion won with 1.6 billion won.

Then, Newstazet R (Samjin Pharmaceutical) and Tamsuall (Dasan Pharmaceutical) followed with 1.3 billion won, and Diqualon (Reyon Pharmaceutical) with 1.2 billion won.

L50 (Boryung Pharmaceutical), Rosu Duo (Cires Pharmaceutical), Kisqali (Novartis), and Atmeg Combigel (Korea United Pharm) recorded 1.1 billion won prescription sales. 

Meanwhile, nearly half of the 11 items, including Akarb, Newstazet R, L50, Rosu Duo, and Atmeg Combigel, are statin combination drugs, showing dyslipidemia combination therapy is still growing. 
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.